CA 125 and HE4: Impact on diagnosis and treatment of early-stage endometrial cancer

Abstract

Endometrial cancer is a major concern in women’s health, being one of the most common gynecological cancers. With favorable prognoses in early stages, diagnostic accuracy and surgical treatment are the challenges. Tumor biomarkers cancer antigen 125 and human epididymis protein four emerge as potential tools, improving early detection. A review was conducted with the aim of evaluating the impact of tumor markers cancer antigen 125 and human epididymis protein four on diagnostic accuracy and surgical treatment of endometrial cancer in early stages. Narrative bibliography generated in scientific review articles, original articles with a maximum of five years of obsolescence 2019-2024 in PubMed, Elsevier and Google Scholar. Combined cancer antigen 125 and human epididymis protein four offer significant sensitivity to detect endometrial cancer in early stages. Although not ideal for primary detection, their combined use in suspected or diagnosed cases provides value in clinical evaluation, and in the prediction of 5-year disease-free survival. This combination of tumor biomarkers emerges as a promising strategy for the diagnosis and preoperative evaluation of endometrial cancer in early stages